Supplementary Material for: ISPAD Clinical Practice Consensus Guidelines 2024 Diabetes Technologies: Glucose Monitoring

SUMMARY OF WHAT IS NEW OR DIFFERENT
Since the 2022 ISPAD Guidelines, there have been advancements in continuous glucose monitoring (CGM) devices and the evidence supporting their use. Research on CGM effectiveness has proliferated, encompassing long-term observational studies, data from registries, and clinical trials.
Changes to previous recommendations include:
1. A stronger emphasis on the pivotal role of CGM in managing diabetes among children and adolescents with Type 1 diabetes (T1D), especially from diabetes diagnosis, as well as potential benefits in youth with Type 2 diabetes (T2D).
2. A greater recognition of the importance of ongoing education and training for both health professionals and families in CGM use, including data interpretation, to ensure successful adoption and to optimize outcomes.
3. Updated information on CGM systems, technical aspects, and key features to guide device suitability and inform individual choice.
4. Increased evidence concerning CGM benefits for decreasing diabetic ketoacidosis (DKA) and severe hypoglycemic events; and improving quality of life in children and adolescents with T1D.
5. Recent developments concerning practical considerations associated with CGM utilization, encompassing topics such as exercise, skin concerns and use in telemedicine.